Functional desensitization of the β2 adrenoceptor is not dependent on agonist efficacy

Pharmacology Research and Perspectives

Volumn 3, Issue 1, 2015, Pages 1-13

  Rosethorne, Elizabeth M ^a,b   Bradley, Michelle E ^a   Kent, Toby C ^a   Charlton, Steven J ^a,b  

^a NOVARTIS INSTITUTES FOR BIOMEDICAL RESEARCH   (United States)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

COPD; Agonist efficacy; Functional desensitization; 2 adrenoceptor

Indexed keywords

AGENTS INTERACTING WITH TRANSMITTER, HORMONE OR DRUG RECEPTORS; BETA 2 ADRENERGIC RECEPTOR; BETA ARRESTIN 2; BETA GALACTOSIDASE; CYCLIC AMP; FORMOTEROL; G PROTEIN COUPLED RECEPTOR AGONIST; ISOPRENALINE; SALMETEROL; UNCLASSIFIED DRUG;

AGONIST; ARTICLE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DRUG EFFICACY; EC50; HUMAN; HUMAN CELL; INTERNALIZATION; PRIORITY JOURNAL; PROTEIN-FRAGMENT COMPLEMENTATION ASSAY; RECEPTOR DOWN REGULATION;

EID: 84941105298     PISSN: None     EISSN: 20521707     Source Type: Journal    
DOI: 10.1002/prp2.101     Document Type: Article

References (33)

1. Aziz I, Tan KS, Hall IP, Devlin MM, Lipworth BJ (1998). Subsensitivity to bronchoprotection against adenosine monophosphate challenge following regular once-daily formoterol. Eur Respir J 12: 580-584.
2. Bhagat R, Kalra S, Swystun VA, Cockroft DW (1995). Rapid onset of tolerance to the bronchoprotective effect of salmeterol. Chest 108: 1235-1239.
3. Calebiro D, Nikolaev VO, Persani L, Lohse MJ (2010). Signaling by internalized G-protein-coupled receptors. Trends Pharmacol Sci 31: 221-228.
4. Carter AA, Hill SJ (2005). Characterization of isoprenaline- and salmeterol-stimulated interactions between beta 2-adrenoceptors and beta-arrestin 2 using beta-galactosidase complementation in C2C12 cells. J Pharmacol Exp Ther 315: 839-848.
5. 2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest 140: 68-75.
6. Charlton SJ (2009). Agonist efficacy and receptor desensitization: from partial truths to a fuller picture. Br J Pharmacol 158: 165-168.
7. Chong LK, Peachell PT (1999). Beta-adrenoceptor reserve in human lung: a comparison between airway smooth muscle and mast cells. Eur J Pharmacol 378: 115-122.
8. Clark RB, Knoll BJ, Barber R (1999). Partial agonists and G protein-coupled receptor desensitization. Trends Pharmacol Sci 20: 279-286.
9. 2-adrenoceptor tolerance in human small airways but via different mechanisms. Br J Pharmacol 163: 521-532.
10. Donohue JF, Van Noord JA, Bateman ED, Langley SJ, Lee A, Witek TJ Jr, et al. (2002). A 6-month, placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 122: 47-55.
11. Donohue JF, Menjoge S, Kesten S (2003). Tolerance to bronchodilating effects of salmeterol in COPD. Respir Med 97: 1014-1020.
12. Donohue JF, Hanania NA, Sciarappa KA, Goodwin E, Grogan DR, Baumgartner RA, et al. (2008). Arformoterol and salmeterol in the treatment of chronic obstructive pulmonary disease: a one year evaluation of safety and tolerance. Ther Adv Respir Dis 2: 37-48.
13. Drotar DE, Davis EE, Cockroft DW (1998). Tolerance to the bronchoprotective effect of salmeterol 12 h after starting twice daily treatment. Ann Allergy Asthma Immunol 80: 31-34.
14. Düringer C, Grundström G, Gürcan E, Dainty IA, Lawson M, Korn SH, et al. (2009). Agonist-specific patterns of beta(2)-adrenoceptor responses in human airway cells during prolonged exposure. Br J Pharmacol 158: 169-179.
15. FitzGerald JM, Chapman KR, Cioppa GD, Stubbing D, Fairbarn MS, Till MD, et al. (1999). Sustained bronchoprotection, bronchodilatation, and symptom control during regular formoterol use in asthma of moderate or greater severity. The Canadian FO/OD1 Study Group. J Allergy Clin Immunol 103: 427-435.
16. Giannini D, Di FA, Bacci E, Dente FL, Vagaggini B, Taccola M, et al. (2011). Tolerance to the protective effect of salmeterol on allergen challenge can be partially restored by the withdrawal of salmeterol regular treatment. Chest 119: 1671-1675.
17. 2-adrenoceptor reserve on human bronchial smooth muscle for some sympathomimetic bronchodilators. Br J Pharmacol 158: 287-299.
18. Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2013. Available at http://www.goldcopd.org/ (Last accessed on 9 October 2014).
19. Hanania NA, Kalberg C, Yates J, Emmett A, Horstman D, Knobil K (2005). The bronchodilator response to salmeterol is maintained with regular, long-term use in patients with COPD. Pulm Pharmacol Ther 18: 19-22.
20. Irannejad R, Tomshine JC, Tomshine JR, Chevalier M, Mahoney JP, Steyaert J, et al. (2013). Conformational biosensors reveal GPCR signalling from endosomes. Nature 495: 534-538.
21. January B, Seibold A, Whaley B, Hipkin RW, Lin D, Schonbrunn A, et al. (1997). beta(2)-adrenergic receptor desensitization, internalization, and phosphorylation in response to full and partial agonists. J Biol Chem 272: 23871-23879.
22. January B, Seibold A, Allal C, Whaley BS, Knoll BJ, Moore RH, et al. (1998). Salmeterol-induced desensitization, internalization and phosphorylation of the human beta(2)-adrenoceptor. Br J Pharmacol 123: 701-711.
23. Kallal L, Gagnon AW, Penn RB, Benovic JL (1998). Visualization of agonist-induced sequestration and down-regulation of a green fluorescent protein-tagged beta2-adrenergic receptor. J Biol Chem 273: 322-328.
24. Krasel C, Vilardaga JP, Bünemann M, Lohse MJ (2004). Kinetics of G-protein-coupled receptor signalling and desensitization. Biochem Soc Trans 32: 1029-1031.
25. McGraw DW, Liggett SB (1997). Heterogeneity in beta-adrenergic receptor kinase expression in the lung accounts for cell-specific desensitization of the beta2-adrenergic receptor. J Biol Chem 272: 7338-7344.
26. Moore RH, Millman EE, Godines V, Hanania NA, Tran TM, Peng H, et al. (2007). Salmeterol Stimulation Dissociates beta2-Adrenergic Receptor Phosphorylation and Internalization. Am J Respir Cell Mol Biol 36: 254-261.
27. Mullershausen F, Zecri F, Cetin C, Billich A, Guerini D, Seuwen K (2009). Persistent signaling induced by FTY720-phosphate is mediated by internalized S1P1 receptors. Nat Chem Biol 5: 428-434.
28. Neubig RR, Spedding M, Kenakin T, Christopoulos A (2003). International Union of Pharmacology Committee on Receptor Nomenclature and Drug Classification. XXXVIII. Update on terms and symbols in quantitative pharmacology. Pharmacol Rev 55: 597-606.
29. Scola AM, Chong LK, Suvarna SK, Chess-Williams R, Peachell PT (2004). Desensitization of mast cell beta2-adrenoceptor-mediated responses by salmeterol and formoterol. Br J Pharmacol 141: 163-171.
30. Scola AM, Loxham M, Charlton SJ, Peachell PT (2009). The long-acting beta2-adrenoceptor agonist, indacaterol, inhibits IgE-dependent responses of human lung mast cells. Br J Pharmacol 158: 267-276.
31. Shenoy SK, Lefkowitz RJ (2005) Seven-transmembrane receptor signaling through beta-arrestin. Science STKE 2005: Cm10.
32. Steffensen I, Faurschou P, Riska H, Rostrup J, Wegener T (1995). Inhaled Formoterol Dry Powder in the Treatment of Patients With Reversible Obstructive Airway Disease. Allergy 50: 657-663.
33. Wei H, Ahn S, Shenoy SK, Karnik SS, Hunyady L, Luttrell LM, et al. (2003). Independent beta-arrestin 2 and G protein-mediated pathways for angiotensin II activation of extracellular signal-regulated kinases 1 and 2. Proc Natl Acad Sci USA 100: 10782-10787.